FOLH1 and posterior cortical atrophy: In March 2022, the PSMA radiopharmaceutical [177Lu]Lu-PSMA-617 was approved by the FDA for the treatment of metastatic castration-resistant PCa following positive results obtained in the VISION trial [7].